← Back to Search

Monoclonal Antibody

Treatment (chemotherapy, transplant) for Chronic Myeloid Leukemia

Phase 2
Waitlist Available
Led By Matthew J Wieduwilt
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights

Study Summary

This study is evaluating whether dasatinib followed by stem cell transplant is better than standard chemotherapy for older patients with newly diagnosed acute lymphoblastic leukemia.

Eligible Conditions
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
Secondary outcome measures
Disease Free Survival (DFS)
Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
Overall Survival (OS)
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (chemotherapy, transplant)Experimental Treatment21 Interventions
See Detailed Description
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3780
Etoposide Phosphate
2011
Completed Phase 2
~160
Filgrastim
2000
Completed Phase 3
~3670
Melphalan
2008
Completed Phase 3
~1500
Methotrexate
2013
Completed Phase 4
~3800
Alemtuzumab
2004
Completed Phase 4
~1890
Allogeneic Hematopoietic Stem Cell Transplantation
2012
Completed Phase 2
~1200
Autologous Hematopoietic Stem Cell Transplantation
2017
Completed Phase 3
~1730
In Vitro-Treated Peripheral Blood Stem Cell Transplantation
2010
Completed Phase 2
~70
Cytarabine
2016
Completed Phase 3
~3310
Dasatinib
2012
Completed Phase 3
~2320
Daunorubicin Hydrochloride
2011
Completed Phase 3
~5070
Dexamethasone
2007
Completed Phase 4
~2590
Fludarabine Phosphate
1997
Completed Phase 3
~2390
Leucovorin Calcium
2011
Completed Phase 3
~12290
Vincristine Sulfate
2005
Completed Phase 3
~10110
Mercaptopurine
2012
Completed Phase 4
~12330
Tacrolimus
2011
Completed Phase 4
~4740
Pegfilgrastim
2013
Completed Phase 3
~4410

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,654 Previous Clinical Trials
40,933,059 Total Patients Enrolled
Matthew J WieduwiltPrincipal InvestigatorAlliance for Clinical Trials in Oncology
1 Previous Clinical Trials
64 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
2010. "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01256398.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top